PURPOSE: To determine the maximum-tolerated dose, dose-limiting toxicities, and pharmacokinetics of the kinesin spindle protein inhibitor ispinesib in pediatric patients with recurrent or refractory solid tumors. SUBJECTS AND METHODS: Ispinesib was administered as 1-hr intravenous infusion weekly × 3, every 28 days. Cohorts of 3-6 patients were enrolled at 5, 7, 9, and 12 mg/m(2) /dose. Serial plasma samples for pharmacokinetic analyses were obtained after the first dose. RESULTS: Twenty-four (13 females) patients with a median (range) age of 10 years (1-19) were enrolled in the study. At the 12 mg/m(2) dose level dose-limiting neutropenia occurred in 2/6 patients and hyperbilirubinemia in 1/6 patients, while at the 9 mg/m(2) dose level 1/6 patients had dose-limiting neutropenia. There were no objective responses, but three patients (diagnoses of anaplastic astrocytoma, alveolar soft part sarcoma, and ependymoblastoma) had stable disease for 4-7 courses. There was substantial interpatient variation in drug disposition. The median (range) terminal elimination half-life was 16 (8-44) hr and the plasma drug clearance was 5 (1-14) L/hr/m(2) . CONCLUSIONS: The maximum tolerated and recommended phase II dose for ispinesib administered weekly × 3 every 28 days for children with solid tumors is 9 mg/m(2) /dose. Plans for a phase II trial in select pediatric solid tumors are in development.
PURPOSE: To determine the maximum-tolerated dose, dose-limiting toxicities, and pharmacokinetics of the kinesin spindle protein inhibitor ispinesib in pediatric patients with recurrent or refractory solid tumors. SUBJECTS AND METHODS: Ispinesib was administered as 1-hr intravenous infusion weekly × 3, every 28 days. Cohorts of 3-6 patients were enrolled at 5, 7, 9, and 12 mg/m(2) /dose. Serial plasma samples for pharmacokinetic analyses were obtained after the first dose. RESULTS: Twenty-four (13 females) patients with a median (range) age of 10 years (1-19) were enrolled in the study. At the 12 mg/m(2) dose level dose-limiting neutropenia occurred in 2/6 patients and hyperbilirubinemia in 1/6 patients, while at the 9 mg/m(2) dose level 1/6 patients had dose-limiting neutropenia. There were no objective responses, but three patients (diagnoses of anaplastic astrocytoma, alveolar soft part sarcoma, and ependymoblastoma) had stable disease for 4-7 courses. There was substantial interpatient variation in drug disposition. The median (range) terminal elimination half-life was 16 (8-44) hr and the plasma drug clearance was 5 (1-14) L/hr/m(2) . CONCLUSIONS: The maximum tolerated and recommended phase II dose for ispinesib administered weekly × 3 every 28 days for children with solid tumors is 9 mg/m(2) /dose. Plans for a phase II trial in select pediatric solid tumors are in development.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Lukas C Kapitein; Erwin J G Peterman; Benjamin H Kwok; Jeffrey H Kim; Tarun M Kapoor; Christoph F Schmidt Journal: Nature Date: 2005-05-05 Impact factor: 49.962
Authors: Weikang Tao; Victoria J South; Yun Zhang; Joseph P Davide; Linda Farrell; Nancy E Kohl; Laura Sepp-Lorenzino; Robert B Lobell Journal: Cancer Cell Date: 2005-07 Impact factor: 31.743
Authors: Peter J Houghton; Christopher L Morton; Chandra Tucker; Debbie Payne; Edward Favours; Claire Cole; Richard Gorlick; E Anders Kolb; Wendong Zhang; Richard Lock; Hernan Carol; Mimi Tajbakhsh; C Patrick Reynolds; John M Maris; Joshua Courtright; Stephen T Keir; Henry S Friedman; Charles Stopford; Joseph Zeidner; Jianrong Wu; Tiebin Liu; Catherine A Billups; Javed Khan; Sherry Ansher; Jian Zhang; Malcolm A Smith Journal: Pediatr Blood Cancer Date: 2007-12 Impact factor: 3.167
Authors: Latesh Lad; Lusong Luo; Jeffrey D Carson; Kenneth W Wood; James J Hartman; Robert A Copeland; Roman Sakowicz Journal: Biochemistry Date: 2008-02-22 Impact factor: 3.162
Authors: Christopher W Lee; Karl Bélanger; Sanjay C Rao; Teresa M Petrella; Richard G Tozer; Lori Wood; Kerry J Savage; Elizabeth A Eisenhauer; Timothy W Synold; Nancy Wainman; Lesley Seymour Journal: Invest New Drugs Date: 2007-10-26 Impact factor: 3.850
Authors: Andrew Castillo; Herbert C Morse; Virginia L Godfrey; Rizwan Naeem; Monica J Justice Journal: Cancer Res Date: 2007-11-01 Impact factor: 12.701
Authors: Roman Sakowicz; Jeffrey T Finer; Christophe Beraud; Anne Crompton; Evan Lewis; Alex Fritsch; Yan Lee; John Mak; Robert Moody; Rebecca Turincio; John C Chabala; Paul Gonzales; Stephanie Roth; Steve Weitman; Kenneth W Wood Journal: Cancer Res Date: 2004-05-01 Impact factor: 12.701
Authors: S P Blagden; L R Molife; A Seebaran; M Payne; A H M Reid; A S Protheroe; L S Vasist; D D Williams; C Bowen; S J Kathman; J P Hodge; M M Dar; J S de Bono; M R Middleton Journal: Br J Cancer Date: 2008-03-04 Impact factor: 7.640
Authors: Edward J Wojcik; Rebecca S Buckley; Jessica Richard; Liqiong Liu; Thomas M Huckaba; Sunyoung Kim Journal: Gene Date: 2013-08-14 Impact factor: 3.688
Authors: Fang Wang; James A D Good; Oliver Rath; Hung Yi Kristal Kaan; Oliver B Sutcliffe; Simon P Mackay; Frank Kozielski Journal: J Med Chem Date: 2012-02-13 Impact factor: 7.446
Authors: Briony F Hudson; Linda Jm Oostendorp; Bridget Candy; Victoria Vickerstaff; Louise Jones; Monica Lakhanpaul; Myra Bluebond-Langner; Paddy Stone Journal: Palliat Med Date: 2016-09-08 Impact factor: 4.762